Summit Therapeutics SMMT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's EPS (diluted)?
- Summit Therapeutics (SMMT) reported EPS (diluted) of -$0.24 in Q1 2026.
- How has Summit Therapeutics's EPS (diluted) changed year-over-year?
- Summit Therapeutics's EPS (diluted) decreased by 166.7% year-over-year, from -$0.09 to -$0.24.
- What is the long-term trend for Summit Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Summit Therapeutics's EPS (diluted) has grown at a 20.6% compound annual growth rate (CAGR), from -$0.68 to -$1.44.
- What does EPS (diluted) mean?
- The profit per share assuming all convertible securities are converted into stock.
- How do you interpret EPS (diluted)?
- A lower diluted EPS compared to basic EPS indicates potential dilution for existing shareholders.
- How does EPS (diluted) compare across companies?
- Standardized metric for comparing earnings potential across companies with different capital structures.